HomeCompareJCRRF vs KMB

JCRRF vs KMB: Dividend Comparison 2026

JCRRF yields 3.22% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JCRRF wins by $590.28M in total portfolio value
10 years
JCRRF
JCRRF
● Live price
3.22%
Share price
$4.17
Annual div
$0.13
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$590.33M
Annual income
$557,098,169.44
Full JCRRF calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — JCRRF vs KMB

📍 JCRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJCRRFKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JCRRF + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JCRRF pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JCRRF
Annual income on $10K today (after 15% tax)
$273.77/yr
After 10yr DRIP, annual income (after tax)
$473,533,444.02/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, JCRRF beats the other by $473,529,005.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JCRRF + KMB for your $10,000?

JCRRF: 50%KMB: 50%
100% KMB50/50100% JCRRF
Portfolio after 10yr
$295.19M
Annual income
$278,551,695.89/yr
Blended yield
94.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

JCRRF
No analyst data
Altman Z
1.4
Piotroski
4/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JCRRF buys
0
KMB buys
0
No recent congressional trades found for JCRRF or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJCRRFKMB
Forward yield3.22%5.25%
Annual dividend / share$0.13$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%17%
Portfolio after 10y$590.33M$45.9K
Annual income after 10y$557,098,169.44$5,222.34
Total dividends collected$587.89M$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: JCRRF vs KMB ($10,000, DRIP)

YearJCRRF PortfolioJCRRF Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,344$644.17$11,314$614.45+$30.00JCRRF
2$13,504$1,365.91$12,867$760.19+$637.00JCRRF
3$17,489$3,039.22$14,713$945.27+$2.8KJCRRF
4$26,070$7,356.96$16,924$1,181.90+$9.1KJCRRF
5$48,393$20,498.67$19,596$1,486.64+$28.8KJCRRF
6$122,906$71,124.57$22,850$1,882.16+$100.1KJCRRF
7$469,147$337,637.75$26,849$2,399.80+$442.3KJCRRF
8$2,910,974$2,408,986.96$31,812$3,083.36+$2.88MJCRRF
9$31,053,709$27,938,966.99$38,033$3,994.72+$31.02MJCRRF
10$590,325,638$557,098,169.44$45,918$5,222.34+$590.28MJCRRF

JCRRF vs KMB: Complete Analysis 2026

JCRRFStock

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Full JCRRF Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this JCRRF vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JCRRF vs SCHDJCRRF vs JEPIJCRRF vs OJCRRF vs KOJCRRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.